|Adult ADHD Home||Succeed at Work||ADHD Self Test|
|Love & Friendships||Manage Time & Money||ADHD Adult Blogs|
|The Organized Life||Stress, Sleep, Health||Adult Support Groups|
|Apps & Gadgets||Inspirational Stories||Expert Answers|
|ADHD Parenting Home||Schedules & Time||Sample Routines|
|Discipline & Behavior||Teens & Young Adults||Parent Support Group|
|ADHD Parenting Skills||Nutrition & Diet||Parenting Blogs|
|Friendships & Social Skills||Sports & Hobbies||Summer & Camps|
|ADHD Treatment Home||ADHD Medications||Medication Reviews||Adderall|
|Treating Your Child||Nutrition & Diet||Fish Oil Printable||Daytrana|
|Expert Q&As||Non-Medical Treatment||Find Professionals||Strattera|
|Behavior Therapy||Brain Training||Quillivant XR||Vyvanse|
|ADHD/LD School Home||High School & College||Accommodations|
|IEPs & 504s||ADHD Study Skills||ADHD School Guide|
|Working with School||School Organization Help||College Survival Guide|
|Social Skills at School||For Teachers Only||Is it LD? A Self Test|
|ADHD Diagnosis Home||ADHD & Women||Is it ADHD? Self Tests|
|Getting a Diagnosis||Is it a Related Condition?||Medical Q&As|
|ADHD Symptoms||Post Diagnosis Next Steps||Myths & Realities|
|Is it Learning Disabilities?||ADHD Treatment||ADHD Support Groups|
|Tools and Checklists|
|ADHD Topics A-Z|
|Share Your Story|
|Give a Gift|
|Buy Back Issues|
FDA Rejects "Black Box" Warning for Stimulant Meds
An FDA advisory group recommends making existing stimulant labels easier to understand.
Thursday June 1st - 12:00am
Filed Under: ADHD Medication and Children
An FDA advisory panel has recommended against requiring pharmaceutical companies to add a "black box" warning label to commonly prescribed AD/HD medications. Instead, the pediatric panel recommended rewriting the current label to make risks and side effects easier to understand.
The recommendation of the panel, whose members are experts in the field of children's health, came one month after a previous FDA panel, composed of drug-safety experts, called for the addition of a black box warning.
The drug-safety panel said they recommended the strong warning label because they believed doctors may be overprescribing AD/HD meds. It acted after Canadian authorities briefly banned sales of Adderall XR last year, because of concerns that the drug contributed to heart failure deaths in children. Critics said no link between the drugs and heart problems had been established.
The FDA will now decide what action to take. The agency is not required to follow the recommendations of its advisory panels.